Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10406160 | INDIVIOR INC | Sustained release small molecule drug formulation |
Jun, 2026
(2 years from now) | |
US9597402 | INDIVIOR INC | Sustained release small molecule drug formulation |
Sep, 2026
(2 years from now) | |
US10058554 | INDIVIOR INC | Sustained release small molecule drug formulation |
Sep, 2026
(2 years from now) | |
US11110093 | INDIVIOR INC | Sustained release small molecule drug formulation |
Nov, 2026
(3 years from now) | |
US11013809 | INDIVIOR INC | Sustained delivery formulations of risperidone compound |
Feb, 2028
(4 years from now) | |
US9180197 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
US9186413 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
US10376590 | INDIVIOR INC | Sustained delivery formulations of risperidone compound |
Feb, 2028
(4 years from now) | |
US10010612 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10592168 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
US9827241 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
US9782402 | INDIVIOR INC | Injectable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
US9272044 | INDIVIOR INC | Injectable flowable composition buprenorphine |
Jun, 2031
(7 years from now) | |
US10198218 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
US9498432 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
US10558394 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jun, 2031
(7 years from now) | |
US8975270 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Sep, 2031
(7 years from now) | |
US8921387 | INDIVIOR INC | Injectable flowable composition comprising buprenorphine |
Jan, 2032
(8 years from now) | |
US11000520 | INDIVIOR INC | Buprenorphine dosing regimens |
Nov, 2035
(12 years from now) | |
US10646484 | INDIVIOR INC | Methods to treat opioid use disorder |
Jun, 2038
(14 years from now) |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treatment of moderate to severe opioid use disorder; Treating opioid dependency by administering buprenorphine; Treating opioid addiction by administration of buprenorphine; Treating opioid dependency...
Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9855221 | INDIVIOR INC | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US9931305 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Feb, 2022
(1 year, 7 months ago) | |
US10285910 | INDIVIOR INC | Sublingual and buccal film compositions |
Oct, 2022
(11 months ago) | |
US8017150 | INDIVIOR INC | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(7 months ago) | |
US8603514 | INDIVIOR INC | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(5 months from now) | |
US9687454 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
US11135216 | INDIVIOR INC | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
US8475832 | INDIVIOR INC | Sublingual and buccal film compositions |
Mar, 2030
(6 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; Treating opioid use disorder; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic